A phase II study of weekly docetaxel and carboplatin in stage IIIB (with effusion) or stage IV non-small cell lung cancer patients age <65 and performance status 2

Autor:	R. Brooker, Lina Asmar, John Sandbach, Charles Weissman, Des Ilegbodu
Rok vydání:	2004
Předmět:	Oncology Cancer Research medicine.medical_specialty Performance status business.industry Phases of clinical research Stage iiib Stage IV non-small cell lung cancer Carboplatin Surgery chemistry.chemical_compound Docetaxel chemistry Effusion Internal medicine Medicine business Stage iv medicine.drug
Zdroj:	Journal of Clinical Oncology. 22:7276-7276
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2004.22.90140.7276
Popis:	7122 Background: Primary goals of therapy for advanced non-small cell lung cancer (ANSCLC) are an increased survival time, palliation of symptoms, and prolonged time to progression (TTP). This study was designed to explore if ANSCLC patients (pts) with ECOG PS 2 and age ≤65 years could benefit from systemic chemotherapy with acceptable toxicities. Methods: Fifty-nine eligible pts with stage IIIB (effusion) or stage IV NSCLC were registered on study. Patients received docetaxel (Taxotere®) 35 mg/m2 and carboplatin AUC=2 on Days 1, 8, 15 every 28-day cycle (maximum 8 cycles). Endpoints were 1-year survival, tumor response, TTP, and safety. Results: Among the 59 eligible pts, 1 never received study drug, 58 pts were evaluable for safety, and 49 for response; 9 pts were non-evaluable due to: palliative XRT (1), withdrawal of consent (2), toxicities (1 each; dyspnea, weakness, allergy to study drug) and other illness (3). Responses were: 1 CR (2%), 5 PR (10%), 22 SD (45%), and 21 PD (43%). The 1-year survival ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2d06ca7b1d4273ecf0a1aa9907c1f0ff https://doi.org/10.1200/jco.2004.22.90140.7276 Zobrazit plný text záznamu